Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd director, Chief Development Officer and founder Dr. Dalia Megiddo filed an initial statement of beneficial ownership of securities. She reports beneficial ownership of 1,888,873 Ordinary Shares held directly.
She also reports indirect beneficial ownership of 5,195 Ordinary Shares held by Formulex Pharma Innovations Ltd, where she is a beneficial owner and may be deemed to beneficially own those shares as well. The filing does not reflect any recent share purchases or sales, only current holdings.
Nasus Pharma Ltd director Israel Isaac filed an initial ownership report showing a stock option position in the company. He holds options to buy 10,000 Ordinary Shares at an exercise price of $5.38 per share, granted on December 11, 2025. The options vest at 2.0833% of the total grant each month after that grant date. As of March 18, 2026, all 10,000 options remain outstanding, of which 625 are vested and exercisable, and the options expire on December 11, 2035.
Nasus Pharma Ltd. registered the resale of up to 5,390,850 Ordinary Shares by the selling shareholders, consisting of 2,695,425 issued shares and 2,695,425 shares issuable upon exercise of Warrants.
This Post-Effective Amendment covers resale only; the Company will not receive proceeds from resales by the selling shareholders but will receive cash if Warrants are exercised. The February 2026 private placement raised $15.0 million and issued Warrants with a $6.53 exercise price (two-year term, with certain early‑exercise limits). The prospectus lists use of potential exercise proceeds for NS002 clinical development and general corporate purposes.
Nasus Pharma filed a Form 6-K highlighting positive Phase 2 data for NS002, its intranasal epinephrine powder for anaphylaxis, and outlining 2026 clinical milestones. The company plans a pivotal NS002 study in the fourth quarter of 2026 with a planned readout in the first quarter of 2027, subject to regulatory alignment. Early-stage programs NS003 for chemotherapy-induced nausea and vomiting and NS004 for metabolic disorders are expected to enter first-in-human studies in the second half of 2026, while NS005 targets cardiovascular diseases.
Financially, Nasus reported cash, cash equivalents and marketable securities of $4.3 million as of December 31, 2025, up from $0.3 million a year earlier, mainly due to its IPO and a subsequent $15 private placement. Research and development expenses rose to $2.4 million from $0.3 million, and general and administrative expenses increased to $2.7 million from $0.7 million, reflecting clinical progress and its transition to a public company. Net loss widened to $5.9 million from $1.5 million. The company expects its cash position to fund operations through the second quarter of 2027 and reported 9,015,383 shares outstanding as of December 31, 2025.
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company developing powder-based intranasal drugs for emergency conditions, led by NS002 intranasal epinephrine and legacy NS001 intranasal naloxone, which is currently paused for partnering. The company has no FDA‑approved products or product revenue and remains in Phase 2 development.
Nasus reported a net loss of $5.9 million in 2025, following $1.5 million in 2024 and $1.1 million in 2023, with an accumulated deficit of about $18.5 million as of December 31, 2025 and 9,015,383 ordinary shares outstanding. Cash and equivalents were approximately $4.3 million at year-end 2025 and $15.0 million as of March 25, 2026, which management expects to fund operations only through the second quarter of 2027. Auditors raised substantial doubt about the company’s ability to continue as a going concern, citing the need for substantial additional capital to complete Phase 2 and 3 trials, manufacturing and commercialization, estimated at $18–$22 million. The filing also discloses material weaknesses in internal controls and extensive clinical, regulatory, financing, competitive and geopolitical risks.
Nasus Pharma reported positive top line Phase 2 results for NS002, its intranasal epinephrine powder for treating anaphylaxis. In 50 healthy adults, NS002 reached the critical 100 pg/mL epinephrine threshold with a median time of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033), with higher proportions of subjects reaching this level within the first minutes.
The company highlighted approximately 50% higher epinephrine exposure in the first 10 minutes versus EpiPen®, similar peak concentrations, and consistent advantages with repeat dosing, all with no serious adverse events. Nasus plans to start a pivotal clinical study in the fourth quarter of 2026 and is hosting a conference call to discuss the data.
Nasus Pharma Ltd. reports that shareholders at a Special General Meeting held on March 5, 2026 approved all agenda items, including a full amendment and restatement of the company’s Articles of Association and an increase in its authorized share capital.
The new Articles set the registered share capital at 50,000,000 no-par value ordinary shares and clarify that all ordinary shares rank equally in rights. They also detail how the company can increase, consolidate, subdivide, or reduce share capital and handle fractional shares, forfeiture, liens, and share repurchases.
The updated Articles formalize governance structures such as a classified three‑class board of directors, procedures for shareholder proposals and director nominations, and rules for general meetings and voting. They also codify indemnification and insurance protections for officers, dividend and capitalization mechanics, and an exclusive U.S. federal forum for Securities Act claims, while keeping Israeli law as the corporate law framework.
Nasus Pharma Ltd. is changing its upcoming Special General Meeting of Shareholders to a fully virtual format because of the security situation in Israel and limits on public gatherings. Shareholders will not be able to attend in person and must join online instead.
The meeting remains scheduled for March 5, 2026 at 2:00 p.m. Israel time. Investors can access the meeting via Zoom using the published meeting link, ID, and passcode, allowing participation and voting remotely while maintaining the original timing of the meeting.
Nasus Pharma Ltd. filed a registration statement on Form F-1 to permit the resale of up to 5,390,850 Ordinary Shares, consisting of 2,695,425 Ordinary Shares held by selling shareholders and 2,695,425 Ordinary Shares issuable upon exercise of warrants. The company will not receive proceeds from resale transactions; it will receive cash only if warrants are exercised.
The prospectus discloses 11,710,808 Ordinary Shares issued and outstanding and a post‑offering adjusted total of 14,406,233 Ordinary Shares assuming full exercise of the Warrants. Recent corporate financings include a February 2026 private placement generating approximately $15.0 million in gross proceeds and interim Phase 2 results reported in January 2026 showing faster systemic absorption and higher peak epinephrine concentrations versus EpiPen; a pivotal study is planned for Q4 2026.